FDA grants fast track designation for olezarsen in familial chylomicronemia syndrome

The FDA has granted fast track designation for olezarsen in the treatment of familial chylomicronemia syndrome, according to a press release from Ionis Pharmaceuticals.Olezarsen is an investigational ligand-conjugated antisense drug developed to inhibit the production of apolipoprotein C-III in patients with elevated triglyceride levels, including those with familial chylomicronemia syndrome (FCS).The FDA’s decision comes after Ionis completed enrollment in 2022 for its global phase 3 BALANCE study of olezarsen in adult patients with FCS.“The FDA fast track designation forRead More